Abstract:Myocardial infarction (MI) is a life-threatening disease resulting from irreversible death of cardiomyocytes (CMs) and weakening of the heart blood-pumping function. Stem cell-based therapies have been studied for MI treatment over the last two decades with promising outcome. In this review, we critically summarize the past work in this field to elucidate the advantages and disadvantages of treating MI using pluripotent stem cells (PSCs) including both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), adult stem cells, and cardiac progenitor cells. The main advantage of the latter is their cytokine production capability to modulate immune responses and control the progression of healing. However, human adult stem cells have very limited (if not 'no') capacity to differentiate into functional CMs in vitro or in vivo. In contrast, PSCs can be differentiated into functional CMs although the protocols for the cardiac differentiation of PSCs are mainly for adherent cells under 2D culture. Derivation of PSC-CMs in 3D, allowing for large-scale production of CMs via modulation of the Wnt/β-catenin signal pathway with defined chemicals and medium, may be desired for clinical translation. Furthermore, the technology of purification and maturation of the PSC-CMs may need further improvements to eliminate teratoma formation after in vivo implantation of the PSC-CMs for treating MI. In addition, in vitro derived PSC-CMs may have mechanical and electrical mismatch with the patient's cardiac tissue, which causes arrhythmia. This supports the use of PSC-derived cells committed to cardiac lineage without beating for implantation to treat MI. In this case, the PSC derived cells may utilize the mechanical, electrical, and chemical cues in the heart to further differentiate into mature/functional CMs in situ. Another major challenge facing stem cell therapy of MI is the low retention/survival of stem cells or their derivatives (e.g., PSC-CMs) in the heart for MI treatment after injection in vivo. This may be resolved by using biomaterials to engineer stem cells for reduced immunogenicity, immobilization of the cells in the heart, and increased integration with the host cardiac tissue. Biomaterials have also been applied in the derivation of CMs in vitro to increase the efficiency and maturation of differentiation. Collectively, a lot has been learned from the past failure of simply injecting intact stem cells or their derivatives in vivo for treating MI, and bioengineering stem cells with biomaterials is expected to be a valuable strategy for advancing stem cell therapy towards its widespread application for treating MI in the clinic.

Human Umbilical Cord Blood for Transplantation Therapy in Myocardial Infarction

Comments about Possible Use of Human Embryonic Stem Cell-Derived Cardiomyocytes to Direct Autologous Adult Stem Cells into the Cardiomyogenic Lineage

Human Umbilical Cord Derived Stem Cells for the Injured Heart

Expanded Human Cord Blood‐derived Endothelial Progenitor Cells Salvage Infarcted Myocardium in Rats with Acute Myocardial Infarction

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

The development of autologous mesenchymal stem cell transplantation in the treatment of myocardial infarction

New Perspectives in the Treatment of Damaged Myocardium Using Autologous Skeletal Myoblasts

Bone marrow-derived stem/progenitor cells: their use in clinical studies for the treatment of myocardial infarction

Angiotensin Receptor Type 2 Stimulation Increases the Migration of Bone-Marrow Mononuclear Cells into the Infarcted Myocardium and Improves Heart Function

A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery.

Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects

Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells

Stem Cell Therapy For Ischemic Heart Diseases

Mesenchymal stem cell delivery strategies to promote cardiac regeneration following ischemic injury

Stem Cell Therapy of Myocardial Infarction: A Promising Opportunity in Bioengineering

Mesenchymal Stem Cells and Mononuclear Cells from Cord Blood: Cotransplantation Provides a Better Effect in Treating Myocardial Infarction.

Transplantation of Human Villous Trophoblasts Preserves Cardiac Function in Mice with Acute Myocardial Infarction

[Stem cell therapy for cardiovascular diseases. Experiences in Düsseldorf]

Combination human umbilical cord perivascular and endothelial colony forming cell therapy for ischemic cardiac injury

Stem Cell-Based Therapy in Cardiac Repair after Myocardial Infarction: Promise, Challenges, and Future Directions

Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction